FCMI
EDIT icon

Foresite Capital Management III’s Editas Medicine EDIT Stock Holding History

Foresite Capital Management III’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-274,910
Closed -$4.46M – 27
2016
Q4 		$4.46M Buy
+274,910
New +$4.17M 1.94% 12
2016
Q2 		– Sell
-14,500
Closed -$501K – 19
2016
Q1 		$501K Buy
+14,500
New +$381K 0.39% 22

Other funds holding EDIT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Foresite Capital Management III's EDIT Position: Q1 2017 in Review

Foresite Capital Management III sold out of Editas Medicine (EDIT) in Q1 2017, closing a stake of 274,910 shares — an estimated $4.46M sold.

Foresite Capital Management III first reported a position in EDIT in Q1 2016 and held it in 2 quarters. The position peaked at $4.46M in Q4 2016. 99 funds tracked by Wall St. Rank hold EDIT as of Q1 2017.

  • Foresite Capital Management III reported no remaining Editas Medicine position as of Q1 2017 after selling out during the quarter.
  • Foresite Capital Management III sold 274,910 Editas Medicine shares in Q1 2017, an estimated $4.46M.
  • Foresite Capital Management III first reported a position in Editas Medicine in Q1 2016 and held it in 2 quarters.
  • Foresite Capital Management III's Editas Medicine position peaked at $4.46M in Q4 2016.
  • 99 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2017.

Based on Foresite Capital Management III's 13F filing for Q1 2017, filed 12 May 2017.